Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 923,553
  • Shares Outstanding, K 62,529
  • Annual Sales, $ 16,100 K
  • Annual Income, $ -198,970 K
  • EBIT $ -185 M
  • EBITDA $ -171 M
  • 60-Month Beta 0.73
  • Price/Sales 60.59
  • Price/Cash Flow N/A
  • Price/Book 4.89

Options Overview Details

View History
  • Implied Volatility 126.25% (-0.07%)
  • Historical Volatility 212.84%
  • IV Percentile 63%
  • IV Rank 24.17%
  • IV High 302.43% on 02/17/26
  • IV Low 70.10% on 04/09/25
  • Expected Move (DTE 17) 2.17 (14.71%)
  • Put/Call Vol Ratio 1.04
  • Today's Volume 2,370
  • Volume Avg (30-Day) 14,948
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 269,132
  • Open Int (30-Day) 288,157
  • Expected Range 12.56 to 16.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.88
  • Number of Estimates 4
  • High Estimate -0.79
  • Low Estimate -1.03
  • Prior Year -0.82
  • Growth Rate Est. (year over year) -7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.73 +68.73%
on 03/03/26
19.22 -23.36%
on 03/10/26
-0.90 (-5.76%)
since 02/27/26
3-Month
8.73 +68.73%
on 03/03/26
28.77 -48.80%
on 01/09/26
-10.08 (-40.63%)
since 12/26/25
52-Week
7.76 +89.82%
on 04/09/25
71.50 -79.40%
on 10/28/25
+2.26 (+18.12%)
since 03/28/25

Most Recent Stories

More News
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit

QURE : 14.73 (-0.27%)
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline

Did you buy QURE   ordinary shares between September 24, 2025, and October 31, 2025 ?

QURE : 14.73 (-0.27%)
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

LOS ANGELES , March 30, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of...

QURE : 14.73 (-0.27%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 30, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure"...

QURE : 14.73 (-0.27%)
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options

QURE : 14.73 (-0.27%)
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS , March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial...

QURE : 14.73 (-0.27%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK , March 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and...

QURE : 14.73 (-0.27%)
QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit

QURE : 14.73 (-0.27%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).   Such investors...

QURE : 14.73 (-0.27%)
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026 - QURE

NEW YORK , March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.

QURE : 14.73 (-0.27%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 15.93
2nd Resistance Point 15.60
1st Resistance Point 15.17
Last Price 14.73
1st Support Level 14.40
2nd Support Level 14.07
3rd Support Level 13.64

See More

52-Week High 71.50
Fibonacci 61.8% 47.15
Fibonacci 50% 39.63
Fibonacci 38.2% 32.11
Last Price 14.73
52-Week Low 7.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.